An interventional study of TearCare System and Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion in Dry Eye and Meibomian Gland Dysfunction, sponsored by Sight Sciences, Inc.. Completed at 14 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 55th largest by enrollment of the 473 interventional ones that give a count, is one of 39 that started in 2021, is one of 136 with no phase, and was the 365th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 39 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 345 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
Sight Sciences, Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.
Sight Sciences, Inc. has 6 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
In this prospective, multicenter, randomized, active-controlled trial, TearCare is compared to cyclosporine 0.05% ophthalmic emulsion (Restasis) in eyes with dry eye disease (DED). Subjects randomized to TearCare receive TearCare treatment at baseline and Month 5, while subjects randomized to Restasis dose twice-daily with Restasis from baseline through Month 6. Primary inference is based on outcomes at the Month 6 visit including the co-primary endpoints tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of any of the following medications:
Any of the following dry eye treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TearCare System
Device: TearCare System
Restasis® (0.05% Cyclosporine ophthalmic emulsion).
Drug: Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Subjects originally randomized to Restasis stop Restasis use at Month 6 and receive a single TearCare treatment at Month 6 and are then followed through Month 12.
Device: TearCare System
TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months.
Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At the Month 6 visit subjects will stop Restasis and receive a single TearCare treatment.
Also known as: Restasis
Tear Break-Up Time
Change in Tear Break-Up Time (TBUT) from baseline to month 6
Time frame: 6 months
OSDI Score
Change in Ocular Surface Disease Index (OSDI) score from baseline to 6-months. The OSDI is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 6 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.
Time frame: 6 months
| Milestone | TearCare Group (Study Device) | Restasis Group (Control) |
|---|---|---|
| Started | 172 | 173 |
| Completed | 155 | 163 |
| Not completed | 17 | 10 |
| Withdrew: Withdrawal by subject | 7 | 7 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Other | 4 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | TearCare Group (Study Device) | Restasis Group (Control) |
|---|---|---|
| Started | 155 | 163 |
| Completed | 142 | 161 |
| Not completed | 13 | 2 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other | 3 | 1 |
Change in Tear Break-Up Time (TBUT) from baseline to month 6
| seconds | TearCare Group (Study Device) | Restasis Group (Control) |
|---|---|---|
| Tear Break-Up Time | 2.71 ± 3.35 | 1.22 ± 2.46 |
Change in Ocular Surface Disease Index (OSDI) score from baseline to 6-months. The OSDI is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 6 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.
| score on a scale | TearCare Group (Study Device) | Restasis Group (Control) |
|---|---|---|
| OSDI Score | -18.25 ± 17.98 | -15.53 ± 19.86 |
Collected over 24 months; TearCare subjects were followed for 24 months while Restasis subjects were followed for 12 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TearCare Group (Study Device) (Baseline to 24 months) | 1/172 (0.6%) | 2/172 (1.2%) | 23/172 (13.4%) |
| Restasis Group (Control) (Baseline to Month 6) | 0/173 (0%) | 0/173 (0%) | 15/173 (8.7%) |
| Restasis Subjects crossed over to TearCare (Month 6- Month 12 | 0/163 (0%) | 0/163 (0%) | 8/163 (4.9%) |
| Event | TearCare Group (Study Device) (Baseline to 24 months) | Restasis Group (Control) (Baseline to Month 6) | Restasis Subjects crossed over to TearCare (Month 6- Month 12 |
|---|---|---|---|
| CholelithiasisGeneral disorders | 1/172 | 0/173 | 0/163 |
| Pulmonary EdemaReproductive system and breast disorders | 1/172 | 0/173 | 0/163 |
| Gall bladder tumorHepatobiliary disorders | 1/172 | 0/173 | 0/163 |
| Event | TearCare Group (Study Device) (Baseline to 24 months) | Restasis Group (Control) (Baseline to Month 6) | Restasis Subjects crossed over to TearCare (Month 6- Month 12 |
|---|---|---|---|
| Loss of BCVA of ≥ 10 lettersEye disorders | 6/172 | 2/173 | 4/163 |
| chalazionEye disorders | 4/172 | 1/173 | 0/163 |
| New Onset Vitreous Floaters and PhotopsiaEye disorders | 0/172 | 3/173 | 1/163 |
| Worsening of Dry EyeEye disorders | 2/172 | 0/173 | 0/163 |
| Swelling of the eyelid(s)Eye disorders | 2/172 | 0/173 | 0/163 |
| macular degenerationEye disorders | 2/172 | 0/173 | 0/163 |
| Foreign body sensationEye disorders | 1/172 | 2/173 | 0/163 |
| Discomfort post instillation of dropsEye disorders | 0/172 | 2/173 | 0/163 |
| Eyelid irritationEye disorders | 1/172 | 0/173 | 1/163 |
| Worsening of Preexisting conditionEye disorders | 0/172 | 0/173 | 1/163 |
| Age, Categorical(Participants) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 113 | 114 | 227 |
| >=65 years | 59 | 59 | 118 |
| Age, Continuous(years) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| Mean | 55.5 ± 14.8 | 56.8 ± 13.1 | 56.2 ± 14.0 |
| Sex: Female, Male(Participants) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| Female | 120 | 128 | 248 |
| Male | 52 | 45 | 97 |
| Race/Ethnicity, Customized(Participants) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| Subject Demographics — Asian | 9 | 7 | 16 |
| Subject Demographics — Black/African American | 6 | 12 | 18 |
| Subject Demographics — White/Caucasian | 155 | 151 | 306 |
| Subject Demographics — Other/mixed | 2 | 3 | 5 |
| Region of Enrollment(participants) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| United States | 172 | 173 | 345 |
| Tear Break Up Time(seconds) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| Mean | 4.39 ± 1.26 | 4.37 ± 1.18 | 4.38 ± 1.21 |
| OSDI(units on a scale) | TearCare Group (Study Device) | Restasis Group (Control) | Total |
|---|---|---|---|
| Mean | 50.0 ± 14.9 | 50.0 ± 14.9 | 50.0 ± 14.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Sep 2024, 40 months.
Results were first posted in Nov 2025, 1 year 2 months after primary completion.
Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 40 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sight Sciences, Inc.